Psychiatry Research: Neuroimaging
Volume 173, Issue 2 , Pages 107-112 , 30 August 2009

The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression

  • Holger Brockmann

      Affiliations

    • Department of Nuclear Medicine, University Bonn, Bonn, Germany
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, University Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. Tel.: +49 228 287 15181; fax: +49 228 287 19096.
    • These authors contributed equally.
  • ,
  • Astrid Zobel

      Affiliations

    • Department of Psychiatry, University Bonn, Bonn, Germany
    • These authors contributed equally.
  • ,
  • Alexius Joe

      Affiliations

    • Department of Nuclear Medicine, University Bonn, Bonn, Germany
  • ,
  • Kim Biermann

      Affiliations

    • Department of Nuclear Medicine, University Bonn, Bonn, Germany
  • ,
  • Lukas Scheef

      Affiliations

    • Department of Radiology, Functional Neuroimaging Group, University Bonn, Bonn, Germany
  • ,
  • Anna Schuhmacher

      Affiliations

    • Department of Psychiatry, University Bonn, Bonn, Germany
  • ,
  • Olrik von Widdern

      Affiliations

    • Department of Psychiatry, University Bonn, Bonn, Germany
  • ,
  • Martin Metten

      Affiliations

    • Department of Psychiatry, University Bonn, Bonn, Germany
  • ,
  • Hans-Juergen Biersack

      Affiliations

    • Department of Nuclear Medicine, University Bonn, Bonn, Germany
  • ,
  • Wolfgang Maier

      Affiliations

    • Department of Psychiatry, University Bonn, Bonn, Germany
  • ,
  • Henning Boecker

      Affiliations

    • Department of Radiology, Functional Neuroimaging Group, University Bonn, Bonn, Germany

Received 20 September 2007 ,Revised 24 October 2008 ,Accepted 28 October 2008.

References 

  1. Acton PD, Friston KJ. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. European Journal of Nuclear Medicine. 1998;25:663–667
  2. Baxter LR, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Archives of General Psychiatry. 1989;46:243–250
  3. Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychological Medicine. 1993;23:579–590
  4. Biver F, Goldman S, Delvenne V, Luxen A, De Maertelaer V, Hubain P, et al. Frontal and parietal metabolic disturbances in unipolar depression. Biological Psychiatry. 1994;36:381–388
  5. Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Research: Neuroimaging. 1999;91:127–139
  6. Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biological Psychiatry. 1997;41:15–22
  7. Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002;27:120–131
  8. Deckersbach T, Dougherty DD, Rauch SL. Functional imaging of mood and anxiety disorders. Journal of Neuroimaging. 2006;16:1–10
  9. Deutsche Gesellschaft für Psychiatrie, P.u.N. . Behandlungsleitlinie Affektive Erkrankungen. Darmstadt, Germany: Steinkopff Verlag; 2000;
  10. Drevets WC. Neuroimaging studies of mood disorders. Biological Psychiatry. 2000;48:813–829
  11. Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824–827
  12. Ebert D, Feistel H, Barocka A. Effects of sleep deprivation on the limbic system and the frontal lobes in affective disorders: a study with Tc-99m-HMPAO SPECT. Psychiatry Research: Neuroimaging. 1991;40:247–251
  13. Ebert D, Feistel H, Barocka A, Kaschka W. Increased limbic blood flow and total sleep deprivation in major depression with melancholia. Psychiatry Research: Neuroimaging. 1994;55:101–109
  14. Galynker II, Cai J, Ongseng F, Finestone H, Dutta E, Serseni D. Hypofrontality and negative symptoms in major depressive disorder. Journal of Nuclear Medicine. 1998;39:608–612
  15. Geday J, Hermansen F, Rosenberg R, Smith DF. Serotonin modulation of cerebral blood flow measured with positron emission tomography (PET) in humans. Synapse. 2005;55:224–229
  16. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62
  17. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. The Journal of Clinical Psychiatry. 2002;63:826–837
  18. Holthoff VA, Beuthien-Baumann B, Zundorf G, Triemer A, Ludecke S, Winiecki P, et al. Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatrica Scandinavica. 2004;110:184–194
  19. Ito H, Kawashima R, Awata S, Ono S, Sato K, Goto R, et al. Hypoperfusion in the limbic system and prefrontal cortex in depression: SPECT with anatomic standardization technique. Journal of Nuclear Medicine. 1996;37:410–414
  20. Joe AY, Tielmann T, Bucerius J, Reinhardt MJ, Palmedo H, Maier W, et al. Response-dependent differences in regional cerebral blood flow changes with citalopram in treatment of major depression. Journal of Nuclear Medicine. 2006;47:1319–1325
  21. Kennedy SH, Javanmard M, Vaccarino FJ. A review of functional neuroimaging in mood disorders: positron emission tomography and depression. Canadian Journal of Psychiatry. 1997;42:467–475
  22. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. The American Journal of Psychiatry. 2001;158:899–905
  23. Kimbrell TA, Ketter TA, George MS, Little JT, Benson BE, Willis MW, et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biological Psychiatry. 2002;51:237–252
  24. Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, et al. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biological Psychiatry. 2005;57:220–228
  25. Mayberg HS. Frontal lobe dysfunction in secondary depression. The Journal of Neuropsychiatry and Clinical Neurosciences. 1994;6:428–442
  26. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. British Medical Bulletin. 2003;65:193–207
  27. Mayberg HS, Lewis PJ, Regenold W, Wagner HN. Paralimbic hypoperfusion in unipolar depression. Journal of Nuclear Medicine. 1994;35:929–934
  28. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, et al. Cingulate function in depression: a potential predictor of treatment response. NeuroReport. 1997;8:1057–1061
  29. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological Psychiatry. 2000;48:830–843
  30. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–660
  31. Mulert C, Juckel G, Brunnmeier M, Leicht SK, Mergl R, Moller HJ, et al. Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication. Clinical EEG and Neuroscience. 2007;38:78–81
  32. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436–1442
  33. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. The American Journal of Psychiatry. 2001;158:405–415
  34. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. The Journal of Clinical Psychiatry. 2006;67:1836–1855
  35. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive–compulsive disorder vs major depression. Archives of General Psychiatry. 2002;59:250–261
  36. Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, Kennedy S, Segal Z, et al. Limbic-frontal circuitry in major depression: a path modeling metanalysis. NeuroImage. 2004;22:409–418
  37. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain perfusion SPET using (99m)Tc-labelled radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29:BP36–BP42
  38. Tutus A, Simsek A, Sofuoglu S, Nardali M, Kugu N, Karaaslan F, et al. Changes in regional cerebral blood flow demonstrated by single photon emission computed tomography in depressive disorders: comparison of unipolar vs. bipolar subtypes. Psychiatry Research: Neuroimaging. 1998;83:169–177
  39. Wu J, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE. Effect of sleep deprivation on brain metabolism of depressed patients. The American Journal of Psychiatry. 1992;149:538–543
  40. Wu J, Buchsbaum MS, Gillin JC, Tang C, Cadwell S, Wiegand M, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. The American Journal of Psychiatry. 1999;156:1149–1158

PII: S0925-4927(08)00174-1

doi: 10.1016/j.pscychresns.2008.10.006

Psychiatry Research: Neuroimaging
Volume 173, Issue 2 , Pages 107-112 , 30 August 2009